Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEquity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Gsk (GLAXF) EPS (Basic) (2017 - 2023)

Historic EPS (Basic) for Gsk (GLAXF) over the last 11 years, with Q1 2023 value amounting to $0.0.

  • Gsk's EPS (Basic) fell 10000.0% to $0.0 in Q1 2023 from the same period last year, while for Mar 2023 it was $0.0, marking a year-over-year decrease of 10000.0%. This contributed to the annual value of $0.81 for FY2024, which is 4658.67% down from last year.
  • According to the latest figures from Q1 2023, Gsk's EPS (Basic) is $0.0, which was down 10000.0% from $2907.8 recorded in Q1 2022.
  • Gsk's 5-year EPS (Basic) high stood at $2907.8 for Q1 2022, and its period low was $0.0 during Q1 2023.
  • Over the past 3 years, Gsk's median EPS (Basic) value was $1811.7 (recorded in 2021), while the average stood at $1655.7.
  • Per our database at Business Quant, Gsk's EPS (Basic) surged by 6735.87% in 2022 and then crashed by 10000.0% in 2023.
  • Gsk's EPS (Basic) (Quarter) stood at $1253.6 in 2021, then skyrocketed by 131.94% to $2907.8 in 2022, then tumbled by 100.0% to $0.0 in 2023.
  • Its EPS (Basic) stands at $0.0 for Q1 2023, versus $2907.8 for Q1 2022 and $1253.6 for Q4 2021.